Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The main objective is to demonstrate the effects of early dopaminergic activation on the
autonomic nervous system in subjects with newly diagnosed vs. established type 2 diabetes.
The primary endpoint is the effect of Bromocriptine QR on changes in autonomic function
measured by assessing sympathetic and parasympathetic function using conventional measures of
autonomic function, including power spectral analysis of heart rate as well as peripheral
autonomic function using sudorimetry and laser scanning of peripheral microvascular autonomic
control.